首页> 外文期刊>Molecular Imaging and Biology >Role of FDG-PET in the Clinical Management of Paraneoplastic Neurological Syndrome: Detection of the Underlying Malignancy and the Brain PET-MRI Correlates
【24h】

Role of FDG-PET in the Clinical Management of Paraneoplastic Neurological Syndrome: Detection of the Underlying Malignancy and the Brain PET-MRI Correlates

机译:FDG-PET在副肿瘤性神经综合征的临床管理中的作用:潜在的恶性肿瘤的检测和脑PET-MRI相关。

获取原文
获取原文并翻译 | 示例
           

摘要

The role of 2-deoxy-2-[F-18]fluoro-d-glucose-positron emission tomography (FDG-PET) imaging in the clinical management of paraneoplastic neurological syndrome (PNS) is in evolution. The initial results are promising, and the potential of this modality in this setting has been demonstrated in the literature. In the setting of PNS, FDG-PET imaging can be of value from the following standpoints: (1) detection of the occult malignant focus and (2) objective assessment of the presence and extent of the functional abnormality in the brain and correlation of the imaging findings with the clinical features and disease activity. For this communication, we have not considered case reports described in the literature, while tabulating the results of the published studies. However, we have referred to important observations made in such reports. In part, this effort has been made because of the relative paucity of the existing literature on this issue. The studies investigating the role of FDG-PET imaging in detecting the sites of malignancy can be divided into two broad categories: (A) studies that incorporated FDG-PET at the initial work up of PNS along with other modalities and (B) studies where FDG-PET was applied after conventional modalities had failed to detect the offending malignancy. While majority of the studies have been of the second category, both categories have demonstrated the incremental role of FDG-PET in the detection of the primary cancer in this setting. Also, it is evident that serial studies at certain intervals should be carried out if the initial FDG-PET scan is negative. The literature describing the central nervous system findings with PET in PNS are primarily restricted to paraneoplastic limbic encephalitis (PLE) and paraneoplastic cerebellar degeneration (PCD). FDG-PET usually shows hypermetabolism in one or both temporal lobes in the setting of paraneoplastic limbic encephalitis, and the magnetic resonance imaging (MRI) findings correlate with the FDG-PET scan results in only a fraction of cases. The functional–anatomic discordance between PET and MRI in PLE needs to be examined further, which might open up new insights into the disease process and might generate further subgroups within this entity. Both modalities complement each other in PLE, and frequently, abnormalities noted on FDG-PET images can provide additional clinical information which is of great value in further patient management. In the setting of paraneoplastic cerebellar degeneration, FDG-PET generally reveals cerebellar hypometabolism similar to the cerebellar atrophy demonstrated by MRI, and FDG-PET tends to show the abnormality more often than MRI.
机译:2-脱氧-2- [F-18]氟-d-葡萄糖-正电子发射断层显像(FDG-PET)成像在副肿瘤性神经综合征(PNS)的临床管理中的作用正在发展。最初的结果令人鼓舞,这种方式在这种情况下的潜力已在文献中得到证明。在PNS的背景下,FDG-PET成像可从以下角度发挥作用:(1)隐匿性恶性病灶的检测;(2)客观评估大脑功能异常的存在和程度以及与脑部功能的相关性影像学表现与临床特征和疾病活动有关。对于这种交流,我们没有考虑文献中描述的病例报告,而是将已发表研究的结果制成表格。但是,我们已经提到了这些报告中的重要意见。在某种程度上,由于有关该问题的现有文献相对较少,所以进行了此努力。有关研究FDG-PET成像在检测恶性部位中的作用的研究可分为两大类:(A)在PNS的初始研究中结合了FDG-PET的研究以及其他方法,以及(B)其中在常规方式未能检测到恶性肿瘤后,应用FDG-PET。尽管大多数研究属于第二类,但这两个类别都证明了FDG-PET在这种情况下检测原发性癌症中的作用日益增加。同样,很明显,如果初始FDG-PET扫描阴性,则应按一定间隔进行系列研究。描述PNS中PET的中枢神经系统发现的文献主要限于副肿瘤性边缘性脑炎(PLE)和副肿瘤性小脑变性(PCD)。在副肿瘤性边缘性脑炎的背景下,FDG-PET通常在一个或两个颞叶显示代谢亢进,而磁共振成像(MRI)的发现仅与一部分病例的FDG-PET扫描结果相关。 PLE中PET和MRI之间的功能-解剖学差异需要进一步检查,这可能会为疾病过程打开新的视野,并可能在该实体内产生更多的亚组。两种方式在PLE中互为补充,并且经常,FDG-PET图像上指出的异常可以提供其他临床信息,这对进一步的患者管理具有重要价值。在副肿瘤性小脑变性的情况下,FDG-PET通常表现出小脑代谢不足,类似于MRI所显示的小脑萎缩,FDG-PET往往比MRI表现出更多的异常。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号